Friday, March 29, 2024

Daily Archives: January 4, 2007

Boston Life Sciences bids $35M for spinal cord drug license

Hopkinton-based Boston Life Sciences Inc. reports it has put up a potential $35 million-plus for an exclusive, worldwide license with BioAxone Therapeutic Inc. of...

Boston Life Sciences Acquires Rights to Develop and Commercialize Promising Phase II Spinal Cord...

Interim Results Report Drug's Safety and Possible Recovery of Function After Debilitating Injury; FDA "Orphan Drug" Status Provides Important Strategic Advantages HOPKINTON, Mass., Jan....

BioAxone Therapeutic Licenses Phase II Spinal Cord Injury Drug Cethrin(R) to Boston Life Sciences

MONTREAL, Jan. 4 /PRNewswire/ - BioAxone Therapeutic announced today that it has licensed its clinical phase II spinal cord injury drug Cethrin to Boston...